INAB (IN8bio) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 28, 2026)


INAB IN8bio Inc INAB
24 GF Score
Price $1.36
View Full Analysis

What is IN8bio Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

IN8bio's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

INAB vs ZIVO, LPCN, CTXR: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, IN8bio's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IN8bio Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where IN8bio's Margin of Safety % (DCF FCF Based) falls into.


INAB
24GF Score
IN8bio Inc INAB
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IN8bio Business Description

Address 350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score

Get the complete analysis for INAB

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price